Palvella Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Palvella Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-123.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 87% of Healthcare companies in United States.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Lower than 61% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Palvella Therapeutics, Inc. made a loss over the last year. Palvella Therapeutics, Inc. owes $0.14 for every $1 it owns. Palvella Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPalvella Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.31The share price is 8.31 times Palvella Therapeutics, Inc.'s book value per share, higher than 83% of Healthcare companies in United States.
Market cap
$1.8 BThe total market value of all of Palvella Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 73% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$217 MWhat Palvella Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$15.05Net worth divided by the number of shares. The share price of $125.10 is 8.3 times this, which is the P/B above.
Return on equity (ROE)
-46.6%Palvella Therapeutics, Inc. lost 46.6% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
Owes vs Owns
0.14×Palvella Therapeutics, Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NonePalvella Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossPalvella Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredPalvella Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashPalvella Therapeutics, Inc. held $57 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Palvella Therapeutics, Inc.: $1.8 B ÷ $217 M (30 Jun 2026) = 8.3.
What is Palvella Therapeutics, Inc.'s return on equity?
Palvella Therapeutics, Inc. lost 46.6% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
How much does Palvella Therapeutics, Inc. owe compared with what it owns?
Palvella Therapeutics, Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does Palvella Therapeutics, Inc. pay a dividend?
No. Palvella Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.